Propanc Biopharma, Inc. (PPCB) Research

Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development. This product is designed to enhance the effectiveness of multiple enzymes that work together to combat cancer. Propanc Biopharma is also engaged in a collaborative research effort with the University of Jaén, initiating the POP1 joint drug discovery program. Founded in 2007, the entity was originally known as Propanc Health Group Corporation before officially changing its name to Propanc Biopharma, Inc. in April 2017. The company's headquarters are located in Camberwell, Australia.

Market snapshot

Symbol
PPCB
Price
$1.47
Day change
-14.04%
Market cap
$1.3M
P/E ratio
-0.07x
52-week range
1.3-270.25
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Cell Source, Inc. (CLCS)
  • Gemina Laboratories Ltd. (GLABF)
  • HOOKIPA Pharma Inc. (HOOK)
  • EOM Pharmaceuticals Holdings, Inc. (IMUC)
  • PreveCeutical Medical Inc. (PRVCF)
  • Quest PharmaTech Inc. (QPTFF)
  • Sirona Biochem Corp. (SRBCF)
  • Synairgen plc (SYGGF)

Recent insider activity

  • ZELINGER JOSEF — A-Award (15000000 shares) on 2023-07-05
  • Kenyon Julian Norman — A-Award (3420000 shares) on 2021-08-17
  • Nathanielsz James Andrew — A-Award (5928000 shares) on 2021-08-17
  • Nathanielsz James Andrew — A-Award (2800000 shares) on 2021-08-17
  • ZELINGER JOSEF — trade (0 shares) on 2021-08-17

Open Propanc Biopharma, Inc. (PPCB) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.